Revolution Medicines to regain rights to cancer candidate from Sanofi

Dec. 08, 2022 12:27 PM ETRevolution Medicines, Inc. (RVMD), SNYAMGNBy: Jonathan Block, SA News Editor

Medical Illustration showing lung cancer or bronchial carcinoma. 3d illustration

Mohammed Haneefa Nizamudeen

  • Sanofi (NASDAQ:SNY) has terminated a development and collaboration agreement with Revolution Medicines (NASDAQ:RVMD) for SHP inhibitor drugs.
  • As a result, Revolution Medicines (RVMD) will regain rights to RMC-4630, a SHP2 inhibitor drug candidate for RAS-addicted

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.